Report Overview

The Ophthalmic diseases drugs market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

According to the National Eye Health Strategy Plan by the Ministry of Health, an estimated 15.5% of Kenyans are in need of quality eye care services, ranging from cataract surgery, diabetic retinopathy care, spectacle corrections and even basic ocular allergy treatment. About 0.7% of all rural Kenyans are blind in their better eye, and another 2.5% have vision which is substantially impaired. In Kenya it is estimated that 4.3% of persons aged above 50 years have the glaucoma disease and cataract contributes almost half (43%) of the total blindness, and 35.9% of the total population have Diabetes Mellitus with Diabetic Retinopathy. Cataract and Glaucoma impact negatively on the quality of life and may influence daily activities such as driving, walking and economic activities. Hence the ophthalmic diseases Drugs market in Kenya will experience enormous growth during the forecasted period.



Market Drivers

The market is majorly driven by the rising prevalence of ophthalmic diseases in Kenya. According to a study, the prevalence of visual impairment was 2.4% among the children aged 0-5 years in Kenya.

The Ophthalmic Division in Kenya has improved the health care and enhanced public awareness on ocular conditions such as refractive error. This has aided in early detection of ocular diseases and management making patients to regain their sight at an early age. The study conducted in Kenya, Nakuru County, estimated that 92,000 adults aged 50years had visual impairment of whom 11,600 were blind, out of a total population of approximately 4.3 million.

The increasing incidence of Ophthalmic diseases and increasing levels of awareness-related to Ophthalmic disease and treatments available are leading to a high growth of Ophthalmic Drugs.

Increase in the effective delivery of eye health care services and appropriate infrastructure for screening and detection of ophthalmic diseases will propel growth in the ophthalmic diseases therapeutic market during the forecasted period.

However, limited number of trained optometrists and human resources hamper growth of the ophthalmic disease Drugs market. Uncertain reimbursement policy is restraining markets growth.